FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.
You may also be interested in...
Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.
Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
As FDA started to reconsider the approval of Roche/Genentech's Avastin for metastatic breast cancer, many were concerned about the decision's potential implications for other applications using progression-free survival as an endpoint.